好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

LACE+ is marginally predictive of 30-day readmission after stroke
Cerebrovascular Disease and Interventional Neurology
P11 - Poster Session 11 (11:45 AM-12:45 PM)
6-027
We aimed to investigate predictors of 30-day same hospital readmission after stroke and incorporate these factors in a predictive model. 
Hospital readmissions after stroke is costly and negatively impact outcomes.
Patients discharged with a primary diagnosis of ischemic stroke and intracerebral hemorrhage between 1/1/2018 and 12/31/2020 were included. Transient Ischemic Attack (TIA) patients were excluded from the analysis. LACE+ index, age, smoking status, primary care physician (PCP) status, type of stroke, admission National Institute of Health Stroke Scale (aNIHSS), thrombolysis and thrombectomy use were compared between patients with or without unplanned 30-day readmission. Logistic regression was used to generate readmission predictive models.  

A total of 3319 patients were identified. Of these 196 TIA patients were excluded from the analysis. Mean age was 67.8 ± 15.27 years. Readmission rate was 9.5% for the whole cohort (ischemic stroke 7.7% and hemorrhagic stroke 14%). Readmitted patients had a high LACE+ score (≥ 60; 73%), low aNIHSS (0-5; 50%), were smokers (61%) and did not have an established PCP (94%) at the time of index admission. Readmitted patients were also less likely to have received thrombolysis (88%) or thrombectomy (80%) during index admission. Logistic regression incorporating LACE+, aNIHSS and stroke type (hemorrhage) were mildly predictive of 30-day unplanned readmission (Model A; c-stat 0.60). Addition of smoking status, alcohol status, primary care physician status, thrombolysis and thrombectomy use slightly improved the predictive ability of the model (Model B; c-stat 0.62).

LACE+ is marginally predictive of 30-day unplanned readmission after stroke. Better scores incorporating socioeconomic, neurological and cerebrovascular variables are needed to predict readmission after stroke.

Authors/Disclosures
Muhib Khan, MD, FAAN (Mayo Clinic)
PRESENTER
The institution of Dr. Khan has received research support from Mayo Clinic 好色先生 Grant . The institution of Dr. Khan has received research support from Mayo Clinic Small Grants .
No disclosure on file
No disclosure on file
No disclosure on file
Malgorzata Miller, MD (Corewell Health) The institution of Dr. Miller has received research support from NIH StrokeNet VERIFY trial.
Jenny P. Tsai, MD (Cleveland Clinic) Dr. Tsai has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerenovus. Dr. Tsai has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Microvention. Dr. Tsai has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. Dr. Tsai has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Q'Apel. Dr. Tsai has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Imperative Care. Dr. Tsai has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Society of NeuroInterventional Surgery.
No disclosure on file
No disclosure on file
Elizabeth Evans, NP (Spectrum Health Medical Group) Mrs. Evans has nothing to disclose.
Nadeem I. Khan, MD (Spectrum Health) Dr. Khan has nothing to disclose.
Nabil Wees, MD (Augusta University) Dr. Wees has nothing to disclose.
Asad Ahrar, MD (Corwell Health) Dr. Ahrar has nothing to disclose.
Jiangyong Min, MD (Corewell Health West) Dr. Min has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic . Dr. Min has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for CredentialMed, LLC. The institution of Dr. Min has received research support from Corerwell Health Foundation .
Michelle D. DeJesus Brazitis, MD (Spectrum Health) Dr. DeJesus Brazitis has nothing to disclose.
No disclosure on file